BioVinc is thrilled to announce it has been awarded a prestigious multi-million dollar SBIR Fast-Track Phase I/II grant from the National Institutes of Health (NIH/NIAID). This funding will accelerate our research and development of cutting-edge treatments targeting infected fractures, a critical unmet medical need.
Patients suffering from open fractures face an alarmingly high risk of infection, often leading to severe complications such as nonunion or amputation, even with the most advanced medical care. Infected fractures are typically addressed through a two-stage procedure, involving systemic and local antibiotic delivery followed by bone grafting. However, current treatment outcomes remain suboptimal. The challenge lies in bacterial colonization, which begins almost immediately after injury and forms a mature biofilm within 5-10 hours. Despite prompt antibiotic administration, a small proportion of bacteria (0.1-10%) can survive, leading to chronic osteomyelitis and impaired graft integration when bone grafts are later applied.
There is an urgent need for innovative dual-purpose therapies that not only deliver antibiotics locally over time but also promote fracture healing.
This grant will support critical large animal model evaluations of BioVinc’s groundbreaking bone-targeted therapy, marking a key step toward IND-enabling studies.
